Developer docs
API playgroundTry for free, no card

Search company profiles

Trialwise

Full company profile

uuid000h3t5

Namestring
Trialwise
Legal namestring
Trialwise, Inc.
Websiteurl
trialwise.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Trialwise, Inc. is a privately held, woman-owned boutique Contract Research Organization incorporated in California and headquartered in Foster City, CA, founded by Beth Brinsdon in 1999 and rebranded under its current name in 2015. The company specializes exclusively in Phase I and II clinical studies, operating with 11-50 employees and a deliberately limited client roster to deliver personalized, high-touch service. Its service portfolio comprises six interconnected modules: Clinical Operations (study management, site/investigator identification, IRB submissions, IP management, TMF), Data Management (CRF/database design, edit checks, data cleaning, coding), Biostatistics (CDISC-compliant programming, SAP design, TLFs, efficacy endpoint analysis with therapeutic expertise in Alzheimer's, Cushing's, Parkinson's, ALS, and clinical pharmacology), Medical Writing (IND support, IBs, protocols, CSRs, safety narratives, trial registration), Staffing Support (temporary and long-term placement across functional areas), and Augmented Services (niche consulting, safety management, QA, medical monitoring, pharmacovigilance).

The company's underlying technology stack centers on clinical trial data management and operations tooling, including eTMF (electronic Trial Master File) and eSource implementations, executed as a cross-functional team without internal silos. A proprietary Risk Adaptive Monitoring Framework, adapted from TransCelerate Biopharma's Risk Based Monitoring initiative and developed since May 2022, was deployed in June 2024 in a multicenter Phase 1 HIV trial. Trialwise operates a referral-driven, sales-led go-to-market, primarily targeting startup and small-to-midsize biotech companies with secondary exposure to Fortune 500 pharmaceutical programs and government/nonprofit research institutions (e.g., SRI International under NIH/NIAID funding). Revenue is generated through professional services contract research agreements; no public pricing exists. Customer acquisition is largely referral-based and relationship-driven rather than marketing-led, with industry-conference presence and earned media (e.g., National Geographic, BBC, NPR coverage of the HOPO 14-1 program) supplementing brand visibility.

Short descriptiontext

Trialwise is a privately held, woman-owned boutique CRO specializing exclusively in Phase I and II clinical studies for startup and small-to-midsize biotech companies, with additional government and Fortune 500 work. It delivers integrated clinical operations, data management, biostatistics, and medical writing services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, contract research organization, Phase I clinical studies, biostatistics services, medical writing services
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Trialwise generates revenue by providing comprehensive clinical trial services including clinical operations, data management, biostatistics, medical writing, and staffing support for Phase I and II clinical studies. Services are provided to sponsors including biotech companies, pharmaceutical companies, and government/research institutions.

trialwise.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Trialwise is a boutique Contract Research Organization (CRO) that delivers integrated Phase I and II clinical study services, including clinical operations, data management, biostatistics, and medical writing, supplemented by staffing support and augmented services such as safety management, quality assurance, medical monitoring, and pharmacovigilance. The firm operates as a cross-functional team embedded within sponsor organizations, serving startup and small-to-midsize biotech companies as well as government and nonprofit research institutions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Trialwise is a boutique Contract Research Organization (CRO) offering an integrated portfolio of six interconnected service modules for Phase I and II clinical studies. The core service suite comprises Clinical Operations (study management, site management, monitoring), Data Management (database design, data cleaning, coding), Biostatistics (statistical analysis, CDISC-compliant programming), and Medical Writing (protocols, CSRs, regulatory documents). Two additional modules—Staffing Support (temporary and long-term placement) and Augmented Services (consulting, safety management, QA, pharmacovigilance)—provide flexibility to scale and customize engagement based on client needs. The company positions itself as a high-touch, collaborative partner for startup and mid-size biotech companies, functioning as an integrated extension of sponsor organizations.

Product and service6 records
1Clinical Operations
CategoryCRO Clinical Operations Services
Description

Comprehensive Phase I/II study management encompassing site/investigator identification and qualification, central IRB submissions including risk-based approaches, investigational product management, Trial Master File management, study-specific plan development, ICF development, source document development, vendor management, and study quality risk identification and management. Provided to biotech and pharmaceutical sponsors for early-phase clinical trials.

2Data Management
3Biostatistics
4Medical Writing
5Staffing Support
6Augmented Services
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-06
Description

Trialwise served as biometrics partner for Phase 1 study of Skye Bioscience's SBI-100 Ophthalmic Emulsion, a first-in-class CB1 receptor agonist for glaucoma treatment. Trialwise created the statistical analysis plan and provided data management, biostatistics, and medical writing services since November 2021. The study demonstrated positive tolerability results in healthy volunteers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-16
Description

Trialwise serves as CRO partner for SRI International's Phase 1 first-in-human clinical trial of HOPO 14-1, an oral treatment for internal radioactive contamination. Trialwise provides clinical operations, data management, biostatistics, and medical writing services. The study is funded by NIH/NIAID (Contract No. 75N93020D00011) and has received media coverage including National Geographic, BBC, and NPR.

3TransCelerate Biopharma
Strategic tierMinorTypeOthers
Description

Trialwise's proprietary Risk Adaptive Monitoring Framework is adapted from TransCelerate Biopharma's Risk Based Monitoring initiative established in 2012. Trialwise adapted this approach for Phase 1 trials with smaller data sets, which proved challenging for traditional RBM implementation.

trialwise.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Celerion is a contract research organization focused on early-phase clinical pharmacology (Phase 1 SAD/MAD, bioequivalence, DDI) and clinical bioanalytical services. Like Trialwise, it specializes in Phase 1 trials serving biotech and pharma sponsors with biometrics and operations under one roof, making it the closest direct comparison.

TypeBroad incumbent
Description

Worldwide Clinical Trials is a mid-size global CRO with Phase I clinical pharmacology and biometrics capabilities. It sits between boutique CROs like Trialwise and tier-1 incumbents, and competes for the same early-phase biotech business.

TypeDirect peer
Description

Altasciences is a mid-size CRO offering early-phase clinical development including first-in-human and biopharmaceutics studies. Its early-phase focus, integrated clinical/biopharma/biometrics offering, and mid-tier positioning make it a directly comparable peer for Trialwise's boutique Phase I/II niche.

TypeBroad incumbent
Description

Medpace is a full-service mid-size CRO with strong early-phase capabilities and an integrated biometrics/medical writing value proposition. While significantly larger and broader than Trialwise, it competes for the same biotech-sponsored Phase I/II work with a similar cross-functional model.

TypeBroad incumbent
Description

PAREXEL is a large global full-service CRO with early-phase, biometrics, and medical writing services. Its Phase I unit competes with Trialwise for biotech and government Phase I/II work, despite PAREXEL's much broader portfolio.

TypeBroad incumbent
Description

ICON is a global full-service CRO offering early-phase through post-approval clinical services. Trialwise competes for Phase I/II biometrics and operations engagements against ICON's early development unit, and ICON's 2021 PRA acquisition materially expanded its Phase 1 footprint.

TypeDirect peer
Description

BASi is a CRO providing early-stage drug development, bioanalytical services, and nonclinical/clinical research. It is comparable to Trialwise as a smaller specialized CRO with discovery through Phase I capabilities and a focus on biotech customers.

TypeBroad incumbent
Description

Charles River provides a comprehensive CRO/CDMO offering including early-phase clinical services (via its Clinical & Discovery Services). Although larger and broader, it overlaps with Trialwise in early-phase clinical operations and biometrics for biotech sponsors.

9Clinipace Worldwide (now Medios Technologies / dMed)
TypeDirect peer
Description

Clinipace is a mid-size CRO focused on small-to-mid biotech and specialty pharma trials, with therapeutic-area expertise in oncology, rare disease, and CNS. Its mid-tier boutique character is comparable to Trialwise's positioning serving similar sponsor segments.

TypeEmerging player
Description

Emmes is a mid-size CRO with strong government and NIH-funded trial experience (similar to Trialwise's SRI/NIAID work). Its biotech and government research focus and biometrics capabilities make it a relevant comparable peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trialwise

Contract Research Organization (CRO) Servicestrialwise.com

Trialwise is a privately held, woman-owned boutique CRO specializing exclusively in Phase I and II clinical studies for startup and small-to-midsize biotech companies, with additional government and Fortune 500 work. It delivers integrated clinical operations, data management, biostatistics, and medical writing services.

What Trialwise does

Trialwise, Inc. is a privately held, woman-owned boutique Contract Research Organization incorporated in California and headquartered in Foster City, CA, founded by Beth Brinsdon in 1999 and rebranded under its current name in 2015. The company specializes exclusively in Phase I and II clinical studies, operating with 11-50 employees and a deliberately limited client roster to deliver personalized, high-touch service. Its service portfolio comprises six interconnected modules: Clinical Operations (study management, site/investigator identification, IRB submissions, IP management, TMF), Data Management (CRF/database design, edit checks, data cleaning, coding), Biostatistics (CDISC-compliant programming, SAP design, TLFs, efficacy endpoint analysis with therapeutic expertise in Alzheimer's, Cushing's, Parkinson's, ALS, and clinical pharmacology), Medical Writing (IND support, IBs, protocols, CSRs, safety narratives, trial registration), Staffing Support (temporary and long-term placement across functional areas), and Augmented Services (niche consulting, safety management, QA, medical monitoring, pharmacovigilance).

The company's underlying technology stack centers on clinical trial data management and operations tooling, including eTMF (electronic Trial Master File) and eSource implementations, executed as a cross-functional team without internal silos. A proprietary Risk Adaptive Monitoring Framework, adapted from TransCelerate Biopharma's Risk Based Monitoring initiative and developed since May 2022, was deployed in June 2024 in a multicenter Phase 1 HIV trial. Trialwise operates a referral-driven, sales-led go-to-market, primarily targeting startup and small-to-midsize biotech companies with secondary exposure to Fortune 500 pharmaceutical programs and government/nonprofit research institutions (e.g., SRI International under NIH/NIAID funding). Revenue is generated through professional services contract research agreements; no public pricing exists. Customer acquisition is largely referral-based and relationship-driven rather than marketing-led, with industry-conference presence and earned media (e.g., National Geographic, BBC, NPR coverage of the HOPO 14-1 program) supplementing brand visibility.

Trialwise firmographics

Firmographics
Name
Trialwise
Legal name
Trialwise, Inc.
Website
https://trialwise.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Trialwise is a privately held, woman-owned boutique CRO specializing exclusively in Phase I and II clinical studies for startup and small-to-midsize biotech companies, with additional government and Fortune 500 work. It delivers integrated clinical operations, data management, biostatistics, and medical writing services.
Ownership category
akta.pro rank

Trialwise industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Clinical trial services
  • Contract research organization
  • Phase I clinical studies
  • Biostatistics services
  • Medical writing services

Where Trialwise is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Trialwise business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Clinical Research Services: Trialwise generates revenue by providing comprehensive clinical trial services including clinical operations, data management, biostatistics, medical writing, and staffing support for Phase I and II clinical studies. Services are provided to sponsors including biotech companies, pharmaceutical companies, and government/research institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Trialwise product offering

Product offering

Core offering

Trialwise is a boutique Contract Research Organization (CRO) that delivers integrated Phase I and II clinical study services, including clinical operations, data management, biostatistics, and medical writing, supplemented by staffing support and augmented services such as safety management, quality assurance, medical monitoring, and pharmacovigilance. The firm operates as a cross-functional team embedded within sponsor organizations, serving startup and small-to-midsize biotech companies as well as government and nonprofit research institutions.

Product overview

Trialwise is a boutique Contract Research Organization (CRO) offering an integrated portfolio of six interconnected service modules for Phase I and II clinical studies. The core service suite comprises Clinical Operations (study management, site management, monitoring), Data Management (database design, data cleaning, coding), Biostatistics (statistical analysis, CDISC-compliant programming), and Medical Writing (protocols, CSRs, regulatory documents). Two additional modules—Staffing Support (temporary and long-term placement) and Augmented Services (consulting, safety management, QA, pharmacovigilance)—provide flexibility to scale and customize engagement based on client needs. The company positions itself as a high-touch, collaborative partner for startup and mid-size biotech companies, functioning as an integrated extension of sponsor organizations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Operations Comprehensive Phase I/II study management encompassing site/investigator identification and qualification, central IRB submissions including risk-based approaches, investigational product management, Trial Master File management, study-specific plan development, ICF development, source document development, vendor management, and study quality risk identification and management. Provided to biotech and pharmaceutical sponsors for early-phase clinical trials.
  • Data Management
  • Biostatistics
  • Medical Writing
  • Staffing Support
  • Augmented Services

Companies that use Trialwise

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Trialwise technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Trialwise partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Skye BiosciencecoreStrategic or Co-development Partner · 6 November 2023Trialwise served as biometrics partner for Phase 1 study of Skye Bioscience's SBI-100 Ophthalmic Emulsion, a first-in-class CB1 receptor agonist for glaucoma treatment. Trialwise created the statistical analysis plan and provided data management, biostatistics, and medical writing services since November 2021. The study demonstrated positive tolerability results in healthy volunteers.
  • SRI InternationalcoreStrategic or Co-development Partner · 16 August 2023Trialwise serves as CRO partner for SRI International's Phase 1 first-in-human clinical trial of HOPO 14-1, an oral treatment for internal radioactive contamination. Trialwise provides clinical operations, data management, biostatistics, and medical writing services. The study is funded by NIH/NIAID (Contract No. 75N93020D00011) and has received media coverage including National Geographic, BBC, and NPR.
  • TransCelerate BiopharmaminorOthersTrialwise's proprietary Risk Adaptive Monitoring Framework is adapted from TransCelerate Biopharma's Risk Based Monitoring initiative established in 2012. Trialwise adapted this approach for Phase 1 trials with smaller data sets, which proved challenging for traditional RBM implementation.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Trialwise competitors and assessment

Company assessment

Direct peers

  • Celerion: Celerion is a contract research organization focused on early-phase clinical pharmacology (Phase 1 SAD/MAD, bioequivalence, DDI) and clinical bioanalytical services. Like Trialwise, it specializes in Phase 1 trials serving biotech and pharma sponsors with biometrics and operations under one roof, making it the closest direct comparison.
  • Altasciences: Altasciences is a mid-size CRO offering early-phase clinical development including first-in-human and biopharmaceutics studies. Its early-phase focus, integrated clinical/biopharma/biometrics offering, and mid-tier positioning make it a directly comparable peer for Trialwise's boutique Phase I/II niche.
  • Bioanalytical Systems Inc (BASi): BASi is a CRO providing early-stage drug development, bioanalytical services, and nonclinical/clinical research. It is comparable to Trialwise as a smaller specialized CRO with discovery through Phase I capabilities and a focus on biotech customers.
  • Clinipace Worldwide (now Medios Technologies / dMed): Clinipace is a mid-size CRO focused on small-to-mid biotech and specialty pharma trials, with therapeutic-area expertise in oncology, rare disease, and CNS. Its mid-tier boutique character is comparable to Trialwise's positioning serving similar sponsor segments.

Broad incumbents

  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO with Phase I clinical pharmacology and biometrics capabilities. It sits between boutique CROs like Trialwise and tier-1 incumbents, and competes for the same early-phase biotech business.
  • Medpace: Medpace is a full-service mid-size CRO with strong early-phase capabilities and an integrated biometrics/medical writing value proposition. While significantly larger and broader than Trialwise, it competes for the same biotech-sponsored Phase I/II work with a similar cross-functional model.
  • PAREXEL International: PAREXEL is a large global full-service CRO with early-phase, biometrics, and medical writing services. Its Phase I unit competes with Trialwise for biotech and government Phase I/II work, despite PAREXEL's much broader portfolio.
  • ICON plc: ICON is a global full-service CRO offering early-phase through post-approval clinical services. Trialwise competes for Phase I/II biometrics and operations engagements against ICON's early development unit, and ICON's 2021 PRA acquisition materially expanded its Phase 1 footprint.
  • Charles River Laboratories: Charles River provides a comprehensive CRO/CDMO offering including early-phase clinical services (via its Clinical & Discovery Services). Although larger and broader, it overlaps with Trialwise in early-phase clinical operations and biometrics for biotech sponsors.

Emerging players

  • Emmes (now part of Optum): Emmes is a mid-size CRO with strong government and NIH-funded trial experience (similar to Trialwise's SRI/NIAID work). Its biotech and government research focus and biometrics capabilities make it a relevant comparable peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Trialwise financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trialwise leadership team

Management profile

Number of profiles

Profiles8 records

Trialwise funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trialwise M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trialwise

What does Trialwise do?

Trialwise is a boutique Contract Research Organization (CRO) that delivers integrated Phase I and II clinical study services, including clinical operations, data management, biostatistics, and medical writing, supplemented by staffing support and augmented services such as safety management, quality assurance, medical monitoring, and pharmacovigilance. The firm operates as a cross-functional team embedded within sponsor organizations, serving startup and small-to-midsize biotech companies as well as government and nonprofit research institutions.

Is Trialwise a public or private company?

Trialwise is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Trialwise founded?

Trialwise was founded in 1999. It employs 11 to 50 people.

Where is Trialwise based?

Trialwise is headquartered in Houston, United States, in the North America region.

How does Trialwise make money?

One revenue line is on record: clinical Research Services.

Who are Trialwise's main competitors?

Direct peers on record are Celerion, Altasciences, Bioanalytical Systems Inc (BASi) and Clinipace Worldwide (now Medios Technologies / dMed). Broad incumbents are Worldwide Clinical Trials, Medpace, PAREXEL International, ICON plc and Charles River Laboratories. Emmes (now part of Optum) is listed as an emerging player.

Does Trialwise have an API?

No public API is recorded for Trialwise.

What industry is Trialwise in?

Trialwise's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales